Progress of neoadjuvant immunotherapy in non-small cell lung cancer
10.3760/cma.j.cn115355-20200828-00493
- VernacularTitle:新辅助免疫治疗在非小细胞肺癌中的研究进展
- Author:
Hanfei GUO
;
Wenqian LI
;
Jiuwei CUI
- From:
Cancer Research and Clinic
2021;33(1):65-69
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitor (ICI) has become one of the important therapeutic strategies for the patients with advanced non-small cell lung cancer (NSCLC). The latest clinical studies have shown that immunotherapy can bring more survival benefits to patients with early lung cancer and operable patients with locally advanced lung cancer. However, the strategies of neoadjuvant immunotherapy, the timing of operation, the evaluation system of curative effect, predictive markers and other problems still need to be explored in the clinical practice of large samples. This paper reviews the progress of neoadjuvant immunotherapy in NSCLC.
